Skip to Content

Join the 'Atezolizumab' group to help and get support from people like you.

Atezolizumab News

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Tretinoin, Fluorouracil, Arimidex, Lupron Depot, Femara, Lung Cancer, Gleevec, Isotretinoin, Rituxan, Non-Small Cell Lung Cancer

Breast Cancer 'Immunotherapy' Helps Some With Tough-to-Treat Disease

Posted 3 Apr 2017 by Drugs.com

MONDAY, April 3, 2017 – Women with a particularly aggressive form of breast cancer who responded to an new immune-focused drug gained a significant survival benefit, a new study shows. The patients all had what's known as advanced, "triple-negative" breast cancers. "Triple-negative breast cancer is an aggressive subtype of breast cancer often affecting younger women and, unfortunately, the current treatment options for metastatic disease remain limited," explained Dr. Peter Schmid. He directs the Breast Centre at St. Bartholomew's Hospital and Barts Cancer Institute in London, England. However, oncologists also stressed that many women who took the new drug, called Tecentriq (atezolizumab), failed to respond. The results of this early, phase 1 trial were to be presented Monday at the annual meeting of the American Academy of Cancer Research (AACR), in Washington, D.C. The trial ... Read more

Related support groups: Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Tecentriq, Atezolizumab

Immune-Focused Drug Shows Promise Against Lung Cancer

Posted 13 Dec 2016 by Drugs.com

TUESDAY, Dec. 13, 2016 – An immunotherapy drug called Tecentriq (atezolizumab) extended the survival of lung cancer patients for several months longer than chemotherapy and caused fewer side effects, according to a new study. The findings are from an early analysis of 850 patients with non-small cell lung cancer in a phase 3 trial funded by the drug's makers. According to the American Cancer Society, non-small cell lung cancer is the major form of the disease, comprising up to 85 percent of cases. Lung cancer remains the leading cancer killer in the United States, with more than 158,000 people expected to die from the disease this year. The patients in the new trial had run out of treatment options. They received either Tecentriq or the chemotherapy drug docetaxel – the standard treatment for this type of cancer. According to a team led by Dr. David Gandara of the University of ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Tecentriq, Atezolizumab

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two cases where patients with advanced melanoma died of heart trouble two weeks after receiving their first doses of Opdivo (nivolumab) and Yervoy (ipilimumab). One patient was a 65-year-old woman who died following a rapid heartbeat and organ failure, while the other patient was a 63-year-old man who died after two rounds of sudden cardiac arrest. With a heart attack, blood flow to the heart is blocked and tissue damage occurs, while in the case of sudden cardiac arrest the heart suddenly stops ... Read more

Related support groups: Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Opdivo, Keytruda, Melanoma - Metastatic, Nivolumab, Tecentriq, Pembrolizumab, Yervoy, Lemtrada, Alemtuzumab, Atezolizumab, Ipilimumab, Campath

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Posted 19 Oct 2016 by Drugs.com

South San Francisco, CA – October 18, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. This approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that Tecentriq helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.74, 95% CI: 0.63, 0.87). The study enrolled people ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Tecentriq, Atezolizumab

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of the American Association for Cancer Research (AACR). The AACR issued the news on immunotherapy as part of its 2016 Cancer Progress Report. As the group explained, more types of cancer are being successfully treated with immunotherapy. This treatment involves adding new cancer-fighting cells to the body or adding new elements, such as antibodies and proteins, to help the immune system fight cancer. In August 2015, one class of immunotherapy drugs – called checkpoint inhibitors – was approved for ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Melanoma, Opdivo, Keytruda, Bladder Cancer, Melanoma - Metastatic, Head and Neck Cancer, Nivolumab, Hodgkin's Lymphoma, Tecentriq, Pembrolizumab, Atezolizumab

Immune-Based Drug May Help Some With Advanced Bladder Cancer

Posted 5 Jun 2016 by Drugs.com

SUNDAY, June 5, 2016 – Patients with advanced bladder cancer can sometimes be too old or unhealthy to withstand standard chemotherapy. However, some may gain hope from a new drug that unleashes the immune system to attack tumor cells, researchers reported Sunday. Patients who responded to the drug Tecentriq (atezolizumab) had an average survival of nearly 15 months, about 5 to 6 months longer than people usually gain from platinum-based chemotherapy, said lead researcher Dr. Arjun Balar. The treatment didn't help everyone, however: Only about a quarter of patients responded to the drug. Still, any advance for this patient population is sorely needed, experts say. That's because about half of advanced bladder cancer patients cannot receive chemotherapy because they're too old to withstand chemo's toxic effects, explained Balar, who is assistant professor of medicine at NYU Langone ... Read more

Related support groups: Cancer, Bladder Cancer, Tecentriq, Atezolizumab

FDA Approves New Drug to Treat Bladder Cancer

Posted 31 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – A new drug to treat bladder cancer was approved by the U.S. Food and Drug Administration on Wednesday. Tecentriq (atezolizumab) treats the most common type of bladder cancer, called urothelial carcinoma. It's the first in its class of drugs, called PD-1/PD-L1 inhibitors, approved to treat this type of cancer. "Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway," Dr. Richard Pazdur, director of the office of hematology and oncology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body's immune system and its interaction with cancer cells," he added. The FDA approved Tecentriq for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has ... Read more

Related support groups: Bladder Cancer, Tecentriq, Atezolizumab

FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma

Posted 18 May 2016 by Drugs.com

May 18, 2016 – The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer. "Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. "Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body’s immune system and its interaction with cancer cells." Tecentriq targets the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells). By blocking these interactions, Tecentriq may help the body’s immune system fight cancer cells. Tecentriq is the first FD ... Read more

Related support groups: Cancer, Bladder Cancer, Tecentriq, Atezolizumab

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Bladder Cancer, Urothelial Carcinoma

Related Drug Support Groups

Tecentriq

Atezolizumab Patient Information at Drugs.com